<?xml version='1.0' encoding='utf-8'?>
<document id="29914955"><sentence text="Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants."><entity charOffset="132-140" id="DDI-PubMed.29914955.s1.e0" text="Imipenem" /><entity charOffset="145-155" id="DDI-PubMed.29914955.s1.e1" text="Cilastatin" /><pair ddi="false" e1="DDI-PubMed.29914955.s1.e0" e2="DDI-PubMed.29914955.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29914955.s1.e0" e2="DDI-PubMed.29914955.s1.e1" /></sentence><sentence text="Relebactam is a novel class A and C β-lactamase inhibitor that is being developed in combination with imipenem-cilastatin for the treatment of serious infections with Gram-negative bacteria" /><sentence text=" Here we report on two phase 1 randomized, double-blind, placebo-controlled pharmacokinetics, safety, and tolerability studies of relebactam administered with or without imipenem-cilastatin to healthy participants: (i) a single-dose (25 to 1,150 mg) and multiple-dose (50 to 625 mg every 6 h [q6h] for 7 to 14 days) escalation study with men and (ii) a single-dose (125 mg) study with women and elderly individuals" /><sentence text=" Following single- or multiple-dose intravenous administration over 30 min, plasma relebactam concentrations declined biexponentially, with a terminal half-life (t1/2) ranging from 1" /><sentence text="35 to 1" /><sentence text="85 h independently of the dose" /><sentence text=" Exposures increased in a dose-proportional manner across the dose range" /><sentence text=" No clinically significant differences in pharmacokinetics between men and women, or between adult and elderly participants, were observed" /><sentence text=" Urine pharmacokinetics demonstrated that urinary excretion is the major route of relebactam elimination" /><sentence text=" No drug-drug interaction between relebactam and imipenem-cilastatin was observed, and the observed t1/2 values for relebactam, imipenem, and cilastatin were comparable, thus supporting coadministration"><entity charOffset="128-136" id="DDI-PubMed.29914955.s10.e0" text="imipenem" /><entity charOffset="142-152" id="DDI-PubMed.29914955.s10.e1" text="cilastatin" /><pair ddi="false" e1="DDI-PubMed.29914955.s10.e0" e2="DDI-PubMed.29914955.s10.e0" /><pair ddi="false" e1="DDI-PubMed.29914955.s10.e0" e2="DDI-PubMed.29914955.s10.e1" /></sentence><sentence text=" Relebactam administered alone or in combination with imipenem-cilastatin was well tolerated across the dose ranges studied" /><sentence text=" No serious adverse events or deaths were reported" /><sentence text=" The pharmacokinetic profile and favorable safety results supported q6h dosing of relebactam with imipenem-cilastatin in clinical treatment trials" /><sentence text="" /></document>